|
Clinical Division Faculty
Satish Garg, MD
Chief, Young Adult Clinics
Professor of Pediatrics & Medicine
BioSketch
Microvascular complications of type I diabetes,
with emphases on:
- the recognition of factors responsible for early diabetic
retinopathy and diabetic nephropathy
- clinical trials of medications to possibly reverse early
changes in eyes and kidneys
- the definition of the early course of microangiopathy
- the evaluation of new, more rapid means of monitoring albumin
excretion rates to assess kidney function
Evaluation and clinical use of new insulin analogues
(short and long acting) as tools for achieving improved glycemic
control in patients with type I diabetes.
Utilization of new insulin administration devices
in the treatment of type I diabetes (pulmonary delivery of insulin
and buccal delivery of insulin).
Glucose sensors: non-invasive glucose monitoring
devices (Glucowatch, infrared ray, continuous subcutaneous glucose
sensors).
Publications:
Garg S, Jovanovic L.
Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor.
Diabetes Care. 2006 Dec;29(12):2644-9.
Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Diabetes Care. 2006 Oct;29(10):2189-95.
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L.
Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.
Diabetes Care. 2006 Jan;29(1):44-50.
Garg SK.
New insulin analogues.
Diabetes Technol Ther. 2005 Oct;7(5):813-7. Review.
Dixon B, Peter Chase H, Burdick J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK.
Use of insulin glargine in children under age 6 with type 1 diabetes.
Pediatr Diabetes. 2005 Sep;6(3):150-4.
Wadwa RP, Kinney GL, Maahs DM, Snell-Bergeon J, Hokanson JE, Garg SK, Eckel RH, Rewers M.
Awareness and treatment of dyslipidemia in young adults with type 1 diabetes.
Diabetes Care. 2005 May;28(5):1051-6.
Garg SK, Ellis SL, Ulrich H.
Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.
Expert Opin Pharmacother. 2005 Apr;6(4):643-51. Review.
Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK.
Inflammatory markers and diabetic retinopathy in type 1 diabetes.
Diabetes Care. 2005 Mar;28(3):714-5.
Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
Diabetes Care. 2005 Mar;28(3):533-8.
Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ.
Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population.
Diabetes Care. 2005 Feb;28(2):301-6.
Garg SK, Rosenstock J, Ways K.
Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.
Endocr Pract. 2005 Jan-Feb;11(1):11-7. Erratum in: Endocr Pract. 2005 Mar-Apr;11(2):145.
Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP.
Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.
Diabetes Res Clin Pract. 2004 Oct;66(1):49-56.
Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA.
Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Diabetes Technol Ther. 2004 Oct;6(5):589-95.
Garg SK, Garg KM, Sabir M.
Evaluation of tocolytic efficacy of selective beta2 adrenoceptor agonists on buffalo uterus.
Indian J Exp Biol. 2004 Sep;42(9):913-8.
Garg SK.
Health impact from frequent and continuous glucose monitoring.
Diabetes Technol Ther. 2004 Aug;6(4):523-4.
Garg SK, Carter JA, Mullen L, Folker AC, Parkes JL, Tideman AM.
The clinical performance and ease of use of a blood glucose meter that uses a 10-test disk.
Diabetes Technol Ther. 2004 Aug;6(4):495-502.
Garg S, Chase HP.
Treatment of adolescents with type 1 diabetes mellitus.
J Pediatr Endocrinol Metab. 2004 May;17(5):805-6.
Weinzimer SA, Tamborlane WV, Chase HP, Garg SK.
Continuous glucose monitoring in type 1 diabetes.
Curr Diab Rep. 2004 Apr;4(2):95-100. Review.
Garg SK, Schwartz S, Edelman SV.
Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes.
Diabetes Care. 2004 Mar;27(3):734-8.
Garg SK, Hoff HK, Chase HP.
The role of continuous glucose sensors in diabetes care.
Endocrinol Metab Clin North Am. 2004 Mar;33(1):163-73, x-xi. Review.
Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP.
Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump.
Diabetes Technol Ther. 2004 Feb;6(1):9-15.
Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK.
Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin.
J Pediatr. 2003 Dec;143(6):737-40.
Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M; The Coronary Artery Calcification in Type 1 Diabetes Study.
Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study.
Diabetes. 2003 Nov;52(11):2833-9. Erratum in: Diabetes. 2004 Aug;53(8):2177.
Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M.
Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control.
Diabetes Care. 2003 Oct;26(10):2923-8.
Chase HP, Pearson JA, Wightman C, Roberts MD, Oderberg AD, Garg SK.
Modem transmission of glucose values reduces the costs and need for clinic visits.
Diabetes Care. 2003 May;26(5):1475-9.
Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE.
Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes.
Endocr Pract. 2003 May-Jun;9(3):187-93.
Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman RC.
Use of the GlucoWatch biographer in children with type 1 diabetes.
Pediatrics. 2003 Apr;111(4 Pt 1):790-4.
Johnston-Brooks CH, Lewis MA, Garg S.
Self-efficacy impacts self-care and HbA1c in young adults with Type I diabetes.
Psychosom Med. 2002 Jan-Feb;64(1):43-51.
Gottlieb PA, Frias JP, Peters KA, Chillara B, Garg SK.
Optimizing insulin therapy in pregnant women with type 1 diabetes mellitus.
Treat Endocrinol. 2002;1(4):235-40. Review.
To access a more complete listing of publications,
please go to PubMed http://www.ncbi.nlm.nih.gov/PubMed/ and use the search term Barbara Davis Center for Childhood
Diabetes or
enter individual author names.
Please direct inquiries to specific e-mail addresses listed
within individual entries. For all other general Research inquiries,
please contact:
kathryn.gray@ucdenver.edu |
|
